News for Antibe Therapeutics Inc. (ATBPF)

TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Antibe Therapeutics Inc. ('Antibe” or the 'Company”) announced that, in connection with its previously announced receivership proceedings, the Company completed a transaction (the 'Transaction”) on March 17, 2025 whereby Taro Pharmaceuticals Inc. (the 'Purchaser”) purchased all of the issued and outstanding common shares of the Company from FTI Consulting Inc. (the 'Receiver”), in its capacity as court-appointed receiver and manager of the Company, pursuant to a transaction agreement (the 'Transaction Agreement”) dated January 15, 2025.

Sun Pharma to acquire 100% stake in Antibe Therapeutics, a Canadian biotech company focused on pain and inflammation drugs.

The NSAIDs market is experiencing significant growth due to the rising incidence of chronic pain and inflammatory conditions such as arthritis and...

Antibe Therapeutics Inc. announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act was heard before...

Antibe Therapeutics Inc. announced that the Company sought an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act at a hearing before the...

TORONTO — Antibe Therapeutics Inc. (“

Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act

TORONTO — Antibe Therapeutics Inc. (“

Antibe Therapeutics Inc. today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration that otenaproxesul has been placed on clinical...

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

- The American Society of Regional Anesthesia and Pain Medicine is the largest subspecialty medical society in anesthesiology ...

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

OTC Markets Group Announces the 2024 OTCQX Best 50 GlobeNewswire January 18, 2024 NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), today announced the 2024 OTCQX® Best 50, a ranking of the top-performing OTCQX companies in the prior calendar year. The OTCQX Best 50 is an...

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), today announced the 2024 OTCQX® Best 50, a ranking of the...

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), today announced the 2024 OTCQX® Best 50, a ranking of the...

TORONTO, Feb. 8, 2021 /CNW/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE), and his team joined Dani Lipkin,